Exploration of Neuroprotective Therapy

S.No	Disease	Sample source	Protein	Method	Reference
1.	AD	Plasma	NFL	ELISA	[78]
2.	AD	CSF	NFL	ELISA	[79]
3.	AD	CSF	NFL	ELISA	[80]
4.	PD	Serum	NFL	Electrochemiluminescence immunoassay	[81]
5.	PD	CSF	NFL	ELISA	[82]
6.	PD	CSF	Ng	ELISA	[83]
7.	HD	CSF	Ng	ELISA	[84]
8.	AD	Blood, CSF	Ng, synaptotagmin 1	ELISA	[85]
9.	AD	CSF	Ng	ELISA	[86]
10.	AD	CSF	Ng	ELISA	[87]

Declarations

Author contributions

VA: Conceptualization, Writing—original draft, Writing—review & editing. SS: Writing—original draft, Writing—review & editing. Both authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Braga EA, Fridman MV, Burdennyy AM, Loginov VI, Dmitriev AA, Pronina IV, et al. Various lncRNA mechanisms in gene regulation involving miRNAs or RNA-binding proteins in non-small-cell lung cancer: main signaling pathways and networks. Int J Mol Sci. 2023;24:13617. [DOI] [PubMed] [PMC]

Hansson O. Biomarkers for neurodegenerative diseases. Nat Med. 2021;27:954–63. [DOI] [PubMed]

Barro C, Zetterberg H. The blood biomarkers puzzle – a review of protein biomarkers in neurodegenerative diseases. J Neurosci Methods. 2021;361:109281. [DOI] [PubMed]

Kelley AS, McGarry K, Gorges R, Skinner JS. The burden of health care costs for patients with dementia in the last 5 years of life. Ann Intern Med. 2015;163:729–36. [DOI] [PubMed] [PMC]

Yang W, Hamilton JL, Kopil C, Beck JC, Tanner CM, Albin RL, et al. Current and projected future economic burden of Parkinson’s disease in the U.S. NPJ Parkinsons Dis. 2020;6:15. [DOI] [PubMed] [PMC]

Klyucherev TO, Olszewski P, Shalimova AA, Chubarev VN, Tarasov VV, Attwood MM, et al. Advances in the development of new biomarkers for Alzheimer’s disease. Transl Neurodegener. 2022;11:25. [DOI] [PubMed] [PMC]

Li T, Le W. Biomarkers for Parkinson’s disease: How good are they? Neurosci Bull. 2020;36:183–94. [DOI] [PubMed] [PMC]

Khoury R, Ghossoub E. Diagnostic biomarkers of Alzheimer’s disease: a state-of-the-art review. Biomark Neuropsychiatry. 2019;1:100005. [DOI]

Durães F, Pinto M, Sousa E. Old drugs as new treatments for neurodegenerative diseases. Pharmaceuticals (Basel). 2018;11:44. [DOI] [PubMed] [PMC]

10.

Bodaghi A, Fattahi N, Ramazani A. Biomarkers: promising and valuable tools towards diagnosis, prognosis and treatment of Covid-19 and other diseases. Heliyon. 2023;9:e13323. [DOI] [PubMed] [PMC]

11.

Craig-Schapiro R, Fagan AM, Holtzman DM. Biomarkers of Alzheimer’s disease. Neurobiol Dis. 2009;35:128–40. [DOI] [PubMed] [PMC]

12.

Babić M, Banović M, Berečić I, Banić T, Babić Leko M, Ulamec M, et al. Molecular biomarkers for the diagnosis, prognosis, and pharmacodynamics of spinal muscular atrophy. J Clin Med. 2023;12:5060. [DOI] [PubMed] [PMC]

13.

Shaw LM, Korecka M, Clark CM, Lee VMY, Trojanowski JQ. Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev Drug Discov. 2007;6:295–303. [DOI] [PubMed]

14.

Wakamatsu K, Chiba Y, Murakami R, Miyai Y, Matsumoto K, Kamada M, et al. Metabolites and biomarker compounds of neurodegenerative diseases in cerebrospinal fluid. Metabolites. 2022;12:343. [DOI] [PubMed] [PMC]

15.

Sharma S, Moon CS, Khogali A, Haidous A, Chabenne A, Ojo C, et al. Biomarkers in Parkinson’s disease (recent update). Neurochem Int. 2013;63:201–29. [DOI] [PubMed]

16.

Meldolesi J. News about the role of fluid and imaging biomarkers in neurodegenerative diseases. Biomedicines. 2021;9:252. [DOI] [PubMed] [PMC]

17.

Sweeney P, Park H, Baumann M, Dunlop J, Frydman J, Kopito R, et al. Protein misfolding in neurodegenerative diseases: implications and strategies. Transl Neurodegener. 2017;6:6. [DOI] [PubMed] [PMC]

18.

Oliveira SR, Dionísio PA, Correia Guedes L, Gonçalves N, Coelho M, Rosa MM, et al. Circulating inflammatory miRNAs associated with Parkinson’s disease pathophysiology. Biomolecules. 2020;10:945. [DOI] [PubMed] [PMC]

19.

Samanta S, Ramesh M, Govindaraju T. Alzheimer’s is a multifactorial disease. In: Govindaraju T, editor. Alzheimer’s disease: recent findings in pathophysiology, diagnostic and therapeutic modalities. Royal Society of Chemistry; 2022. pp. 1–34.

20.

Vasek MJ, Garber C, Dorsey D, Durrant DM, Bollman B, Soung A, et al. A complement–microglial axis drives synapse loss during virus-induced memory impairment. Nature. 2016;534:538–43. [DOI] [PubMed] [PMC]

21.

Uryu K, Chen XH, Martinez D, Browne KD, Johnson VE, Graham DI, et al. Multiple proteins implicated in neurodegenerative diseases accumulate in axons after brain trauma in humans. Exp Neurol. 2007;208:185–92. [DOI] [PubMed] [PMC]

22.

Williams DR, Holton JL, Strand C, Pittman A, De Silva R, Lees AJ, et al. Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson’s syndrome. Brain. 2007;130:1566–76. [DOI] [PubMed]

23.

Miller DB, O’Callaghan JP. Biomarkers of Parkinson’s disease: present and future. Metabolism. 2015;64:S40–6. [DOI] [PubMed] [PMC]

24.

Pospelova M, Krasnikova V, Fionik O, Alekseeva T, Samochernykh K, Ivanova N, et al. Potential molecular biomarkers of central nervous system damage in breast cancer survivors. J Clin Med. 2022;11:1215. [DOI] [PubMed] [PMC]

25.

Ehrenberg AJ, Khatun A, Coomans E, Betts MJ, Capraro F, Thijssen EH, et al. Relevance of biomarkers across different neurodegenerative. Alzheimers Res Ther. 2020;12:56. [DOI] [PubMed] [PMC]

26.

Zehravi M, Kabir J, Akter R, Malik S, Ashraf GM, Tagde P, et al. A prospective viewpoint on neurological diseases and their biomarkers. Molecules. 2022;27:3516. [DOI] [PubMed] [PMC]

27.

Rahimian P, He JJ. HIV/neuroAIDS biomarkers. Prog Neurobiol. 2017;157:117–32. [DOI] [PubMed] [PMC]

28.

Mattsson N. CSF biomarkers in neurodegenerative diseases. Clin Chem Lab Med. 2011;49:345–52. [DOI] [PubMed]

29.

Siedlecki-Wullich D, Miñano-Molina AJ, Rodríguez-Álvarez J. microRNAs as early biomarkers of Alzheimer’s disease: a synaptic perspective. Cells. 2021;10:113. [DOI] [PubMed] [PMC]

30.

Ivey KN, Srivastava D. microRNAs as developmental regulators. Cold Spring Harb Perspect Biol. 2015;7:a008144. [DOI] [PubMed] [PMC]

31.

Roy B, Lee E, Li T, Rampersaud M. Role of miRNAs in neurodegeneration: from disease cause to tools of biomarker discovery and therapeutics. Genes (Basel). 2022;13:425. [DOI] [PubMed] [PMC]

32.

Nies YH, Mohamad Najib NH, Lim WL, Kamaruzzaman MA, Yahaya MF, Teoh SL. MicroRNA dysregulation in Parkinson’s disease: a narrative review. Front Neurosci. 2021;15:660379. [DOI] [PubMed] [PMC]

33.

Skog J, Würdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008;10:1470–6. [DOI] [PubMed] [PMC]

34.

Song MY, Pan KF, Su HJ, Zhang L, Ma JL, Li JY, et al. Identification of serum microRNAs as novel non-invasive biomarkers for early detection of gastric cancer. PLoS One. 2012;7:e33608. [DOI] [PubMed] [PMC]

35.

Citterio LA, Mancuso R, Agostini S, Meloni M, Clerici M. Serum and exosomal miR-7-1-5p and miR-223-3p as possible biomarkers for Parkinson’s disease. Biomolecules. 2023;13:865. [DOI] [PubMed] [PMC]

36.

Riva P, Ratti A, Venturin M. The long non-coding RNAs in neurodegenerative diseases: novel mechanisms of pathogenesis. Curr Alzheimer Res. 2016;13:1219–31. [DOI] [PubMed]

37.

Zhang M, He P, Bian Z. Long noncoding RNAs in neurodegenerative diseases: pathogenesis and potential implications as clinical biomarkers. Front Mol Neurosci. 2021;14:685143. [DOI] [PubMed] [PMC]

38.

Sopher BL, Ladd PD, Pineda VV, Libby RT, Sunkin SM, Hurley JB, et al. CTCF regulates ataxin-7 expression through promotion of a convergently transcribed, antisense noncoding RNA. Neuron. 2011;70:1071–84. [DOI] [PubMed] [PMC]

39.

Peschansky VJ, Pastori C, Zeier Z, Wentzel K, Velmeshev D, Magistri M, et al. The long non-coding RNA FMR4 promotes proliferation of human neural precursor cells and epigenetic regulation of gene expression in trans. Mol Cell Neurosci. 2016;74:49–57. [DOI] [PubMed]

40.

Doxakis E. Insights into the multifaceted role of circular RNAs: implications for Parkinson’s disease pathogenesis and diagnosis. NPJ Parkinsons Dis. 2022;8:7. [DOI] [PubMed] [PMC]

41.

Sheinerman KS, Umansky SR. Circulating cell-free microRNA as biomarkers for screening, diagnosis, and monitoring of neurodegenerative diseases and other neurologic pathologies. Front Cell Neurosci. 2013;7:150. [DOI] [PubMed] [PMC]

42.

van den Berg MMJ, Krauskopf J, Ramaekers JG, Kleinjans JCS, Prickaerts J, Briedé JJ. Circulating microRNAs as potential biomarkers for psychiatric and neurodegenerative disorders. Prog Neurobiol. 2020;185:101732. [DOI] [PubMed]

43.

Patop IL, Wüst S, Kadener S. Past, present, and future of circRNAs. EMBO J. 2019;38:e100836. [DOI] [PubMed] [PMC]

44.

Koníčková D, Menšíková K, Tučková L, Hényková E, Strnad M, Friedecký D, et al. Biomarkers of neurodegenerative diseases: biology, taxonomy, clinical relevance, and current research status. Biomedicines. 2022;10:1760. [DOI] [PubMed] [PMC]

45.

Dube U, Del-Aguila JL, Li Z, Budde JP, Jiang S, Hsu S, et al. An atlas of cortical circular RNA expression in Alzheimer disease brains demonstrates clinical and pathological associations. Nat Neurosci. 2019;22:1903–12. [DOI] [PubMed] [PMC]

46.

Basu A, Ash PEA, Wolozin B, Emili A. Protein interaction network biology in neuroscience. Proteomics. 2021;21:1900311. [DOI] [PubMed] [PMC]

47.

Xu J, Chatterjee M, Baguley TD, Brouillette J, Kurup P, Ghosh D, et al. Inhibitor of the tyrosine phosphatase step reverses cognitive deficits in a mouse model of Alzheimer’s disease. PLoS Biol. 2014;12:e1001923. [DOI] [PubMed] [PMC]

48.

Bassett DS, Gazzaniga MS. Understanding complexity in the human brain. Trends Cogn Sci. 2011;15:200–9. [DOI] [PubMed] [PMC]

49.

Gradišnik L, Bošnjak R, Bunc G, Ravnik J, Maver T, Velnar T. Neurosurgical approaches to brain tissue harvesting for the establishment of cell cultures in neural experimental cell models. Materials (Basel). 2021;14:6857. [DOI] [PubMed] [PMC]

50.

Dakterzada F, David Benítez I, Targa A, Lladó A, Torres G, Romero L, et al. Reduced levels of miR-342-5p in plasma are associated with worse cognitive evolution in patients with mild Alzheimer’s disease. Front Aging Neurosci. 2021;13:705989. [DOI] [PubMed] [PMC]

51.

Barros-Viegas AT, Carmona V, Ferreiro E, Guedes J, Cardoso AM, Cunha P, et al. miRNA-31 improves cognition and abolishes amyloid-β pathology by targeting APP and BACE1 in an animal model of Alzheimer’s disease. Mol Ther Nucleic Acids. 2020;19:1219–36. [DOI] [PubMed] [PMC]

52.

Xu N, Li AD, Ji LL, Ye Y, Wang ZY, Tong L. miR-132 regulates the expression of synaptic proteins in APP/PS1 transgenic mice through C1q. Eur J Histochem. 2019;63:3008. [DOI] [PubMed] [PMC]

53.

Sun S, Han X, Li X, Song Q, Lu M, Jia M, et al. MicroRNA-212-5p prevents dopaminergic neuron death by inhibiting SIRT2 in MPTP-induced mouse model of Parkinson’s disease. Front Mol Neurosci. 2018;11:381. [DOI] [PubMed] [PMC]

54.

Feng CZ, Yin JB, Yang JJ, Cao L. Regulatory factor X1 depresses ApoE-dependent Aβ uptake by miRNA-124 in microglial response to oxidative stress. Neuroscience. 2017;344:217–28. [DOI] [PubMed]

55.

Kim SJ, Russell AE, Wang W, Gemoets DE, Sarkar SN, Simpkins JW, et al. miR-146a dysregulates energy metabolism during neuroinflammation. J Neuroimmune Pharmacol. 2022;17:228–41. [DOI] [PubMed] [PMC]

56.

Shi Z, Zhang K, Zhou H, Jiang L, Xie B, Wang R, et al. Increased miR-34c mediates synaptic deficits by targeting synaptotagmin 1 through ROS-JNK-p53 pathway in Alzheimer’s disease. Aging Cell. 2020;19:e13125. [DOI] [PubMed] [PMC]

57.

Wu Q, Xi DZ, Wang YH. MicroRNA-599 regulates the development of Parkinson’s disease through mediating LRRK2 expression. Eur Rev Med Pharmacol Sci. 2019;23:724–31. [DOI] [PubMed]

58.

Su C, Yang X, Lou J. Geniposide reduces α-synuclein by blocking microRNA-21/lysosome-associated membrane protein 2A interaction in Parkinson disease models. Brain Res. 2016;1644:98–106. [DOI] [PubMed]

59.

Qin X, Zhang X, Li P, Wang M, Yan L, Pan P, et al. MicroRNA-185 activates PI3K/AKT signalling pathway to alleviate dopaminergic neuron damage via targeting IGF1 in Parkinson’s disease. J Drug Target. 2021;29:875–83. [DOI] [PubMed]

60.

Alural B, Ozerdem A, Allmer J, Genc K, Genc S. Lithium protects against paraquat neurotoxicity by NRF2 activation and miR-34a inhibition in SH-SY5Y cells. Front Cell Neurosci. 2015;9:209. [DOI] [PubMed] [PMC]

61.

Wan Z, Rasheed M, Li Y, Li Q, Wang P, Li J, et al. miR-218-5p and miR-320a-5p as biomarkers for brain disorders: focus on the major depressive disorder and Parkinson’s disease. Mol Neurobiol. 2023;60:5642–54. [DOI] [PubMed]

62.

Scheper M, Iyer A, Anink JJ, Mesarosova L, Mills JD, Aronica E. Dysregulation of miR-543 in Parkinson’s disease: impact on the neuroprotective gene SIRT1. Neuropathol Appl Neurobiol. 2023;49:e12864. [DOI] [PubMed] [PMC]

63.

Hoss AG, Labadorf A, Beach TG, Latourelle JC, Myers RH. microRNA profiles in Parkinson’s disease prefrontal cortex. Front Aging Neurosci. 2016;8:36. [DOI] [PubMed] [PMC]

64.

Li B, Jiang Y, Xu Y, Li Y, Li B. Identification of miRNA-7 as a regulator of brain-derived neurotrophic factor/α-synuclein axis in atrazine-induced Parkinson’s disease by peripheral blood and brain microRNA profiling. Chemosphere. 2019;233:542–8. [DOI] [PubMed]

65.

Rai S, Bharti PS, Singh R, Rastogi S, Rani K, Sharma V, et al. Circulating plasma miR-23b-3p as a biomarker target for idiopathic Parkinson’s disease: comparison with small extracellular vesicle miRNA. Front Neurosci. 2023;17:1174951. [DOI] [PubMed] [PMC]

66.

Li L, Ren J, Pan C, Li Y, Xu J, Dong H, et al. Serum miR-214 serves as a biomarker for prodromal Parkinson’s disease. Front Aging Neurosci. 2021;13:700959. [DOI] [PubMed] [PMC]

67.

Chen Q, Deng N, Lu K, Liao Q, Long X, Gou D, et al. Elevated plasma miR-133b and miR-221-3p as biomarkers for early Parkinson’s disease. Sci Rep. 2021;11:15268. [DOI] [PubMed] [PMC]

68.

Jiang Y, Chen J, Sun Y, Li F, Wei L, Sun W, et al. Profiling of differentially expressed microRNAs in saliva of Parkinson’s disease patients. Front Neurol. 2021;12:738530. [DOI] [PubMed] [PMC]

69.

Dong H, Li J, Huang L, Chen X, Li D, Wang T, et al. Serum MicroRNA profiles serve as novel biomarkers for the diagnosis of Alzheimer’s disease. Dis Markers. 2015;2015:625659. [DOI] [PubMed] [PMC]

70.

Chopra N, Wang R, Maloney B, Nho K, Beck JS, Pourshafie N, et al. MicroRNA-298 reduces levels of human amyloid-β precursor protein (APP), β-site APP-converting enzyme 1 (BACE1) and specific tau protein moieties. Mol Psychiatry. 2021;26:5636–57. [DOI] [PubMed] [PMC]

71.

Chia SY, Vipin A, Ng KP, Tu H, Bommakanti A, Wang BZ, et al. Upregulated blood miR-150-5p in Alzheimer’s disease dementia is associated with cognition, cerebrospinal fluid amyloid-β, and cerebral atrophy. J Alzheimers Dis. 2022;88:1567–84. [DOI] [PubMed]

72.

Zhao X, Wang S, Sun W. Expression of miR-28-3p in patients with Alzheimer’s disease before and after treatment and its clinical value. Exp Ther Med. 2020;2218–26. [DOI] [PubMed] [PMC]

73.

Zhang M, Han W, Xu Y, Li D, Xue Q. Serum miR-128 serves as a potential diagnostic biomarker for Alzheimer’s disease. Neuropsychiatr Dis Treat. 2021;17:269–75. [DOI] [PubMed] [PMC]

74.

Kumar S, Vijayan M, Reddy PH. MicroRNA-455-3p as a potential peripheral biomarker for Alzheimer’s disease. Hum Mol Genet. 2017;26:3808–22. [DOI] [PubMed] [PMC]

75.

Han SW, Pyun JM, Bice PJ, Bennett DA, Saykin AJ, Kim SY. miR-129-5p as a biomarker for pathology and cognitive decline in Alzheimer’s disease. Alzheimers Res Ther. 2024;16:5. [DOI] [PubMed] [PMC]

76.

Liu Q, Lei C. Neuroprotective effects of miR-331-3p through improved cell viability and inflammatory marker expression: correlation of serum miR-331-3p levels with diagnosis and severity of Alzheimer’s disease. Exp Gerontol. 2021;144:111187. [DOI] [PubMed]

77.

Wang J, Chen C, Zhang Y. An investigation of microRNA-103 and microRNA-107 as potential blood-based biomarkers for disease risk and progression of Alzheimer’s disease. J Clin Lab Anal. 2020;34:e23006. [DOI] [PubMed] [PMC]

78.

Mattsson N, Andreasson U, Zetterberg H, Blennow K; Alzheimer’s Disease Neuroimaging Initiative. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2017;74:557–66. [DOI] [PubMed] [PMC]

79.

Delaby C, Alcolea D, Carmona-Iragui M, Illán-Gala I, Morenas-Rodríguez E, Barroeta I, et al. Differential levels of neurofilament light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders. Sci Rep. 2020;10:9161. [DOI] [PubMed] [PMC]

80.

Agnello L, Lo Sasso B, Vidali M, Scazzone C, Piccoli T, Gambino CM, et al. Neurogranin as a reliable biomarker for synaptic dysfunction in Alzheimer’s disease. Diagnostics (Basel). 2021;11:2339. [DOI] [PubMed] [PMC]

81.

Huang Y, Huang C, Zhang Q, Shen T, Sun J. Serum NFL discriminates Parkinson disease from essential tremor and reflect motor and cognition severity. BMC Neurol. 2022;22:39. [DOI] [PubMed] [PMC]

82.

Papuć E, Rejdak K. Increased CSF NFL in non-demented Parkinson’s disease subjects reflects early white matter damage. Front Aging Neurosci. 2020;12:128. [DOI] [PubMed] [PMC]

83.

Bereczki E, Bogstedt A, Höglund K, Tsitsi P, Brodin L, Ballard C, et al. Synaptic proteins in CSF relate to Parkinson’s disease stage markers. NPJ Parkinsons Dis. 2017;3:7. [DOI] [PubMed] [PMC]

84.

Byrne LM, Rodrigues FB, Johnson EB, De Vita E, Blennow K, Scahill R, et al. Cerebrospinal fluid neurogranin and TREM2 in Huntington’s disease. Sci Rep. 2018;8:4260. [DOI] [PubMed] [PMC]

85.

Jia L, Zhu M, Kong C, Pang Y, Zhang H, Qiu Q, et al. Blood neuro-exosomal synaptic proteins predict Alzheimer’s disease at the asymptomatic stage. Alzheimers Dement. 2021;17:49–60. [DOI] [PubMed] [PMC]

86.

Kivisäkk P, Carlyle BC, Sweeney T, Quinn JP, Ramirez CE, Trombetta BA, et al. Increased levels of the synaptic proteins PSD-95, SNAP-25, and neurogranin in the cerebrospinal fluid of patients with Alzheimer’s disease. Alzheimers Res Ther. 2022;14:58. [DOI] [PubMed] [PMC]

87.

Casaletto KB, Elahi FM, Bettcher BM, Neuhaus J, Bendlin BB, Asthana S, et al. Neurogranin, a synaptic protein, is associated with memory independent of Alzheimer biomarkers. Neurology. 2017;89:1782–8. [DOI] [PubMed] [PMC]

88.

Ambros V. The functions of animal microRNAs. Nature. 2004;431:350–5. [DOI] [PubMed]

89.

Maniati MS, Maniati M, Yousefi T, Ahmadi-Ahangar A, Tehrani SS. New insights into the role of microRNAs and long noncoding RNAs in most common neurodegenerative diseases. J Cell Biochem. 2019;120:8908–18. [DOI] [PubMed]

90.

Rashidi SK, Kalirad A, Rafie S, Behzad E, Dezfouli MA. The role of microRNAs in neurobiology and pathophysiology of the hippocampus. Front Mol Neurosci. 2023;16:1226413. [DOI] [PubMed] [PMC]

91.

Viswambharan V, Thanseem I, Vasu MM, Poovathinal SA, Anitha A. MiRNAs as biomarkers of neurodegenerative disorders. Biomark Med. 2017;11:151–67. [DOI] [PubMed]

92.

Nagaraj S, Zoltowska KM, Laskowska-Kaszub K, Wojda U. microRNA diagnostic panel for Alzheimer’s disease and epigenetic trade-off between neurodegeneration and cancer. Ageing Res Rev. 2019;49:125–43. [DOI] [PubMed]

93.

Guedes JR, Santana I, Cunha C, Duro D, Almeida MR, Cardoso AM, et al. MicroRNA deregulation and chemotaxis and phagocytosis impairment in Alzheimer’s disease. Alzheimers Dement (Amst). 2015;3:7–17. [DOI] [PubMed] [PMC]

94.

Nagaraj S, Laskowska-Kaszub K, Debski KJ, Wojsiat J, Dabrowski M, Gabryelewicz T, et al. Profile of 6 microRNA in blood plasma distinguish early stage Alzheimer’s disease patients from non-demented subjects. Oncotarget. 2017;8:16122–43. [DOI] [PubMed] [PMC]

95.

Condrat CE, Thompson DC, Barbu MG, Bugnar OL, Boboc A, Cretoiu D, et al. miRNAs as biomarkers in disease: latest findings regarding their role in diagnosis and prognosis. Cells. 2020;9:276. [DOI] [PubMed] [PMC]

96.

Wang J, Zhang KY, Liu SM, Sen S. Tumor-associated circulating microRNAs as biomarkers of cancer. Molecules. 2014;19:1912–38. [DOI] [PubMed] [PMC]

97.

Wang J, Chen J, Sen S. MicroRNA as biomarkers and diagnostics. J Cell Physiol. 2016;231:25–30. [DOI] [PubMed] [PMC]

98.

Marques TM, Kuiperij HB, Bruinsma IB, van Rumund A, Aerts MB, Esselink RAJ, et al. MicroRNAs in cerebrospinal fluid as potential biomarkers for Parkinson’s disease and multiple system atrophy. Mol Neurobiol. 2017;54:7736–45. [DOI] [PubMed] [PMC]

99.

Fan Y, Li J, Yang Q, Gong C, Gao H, Mao Z, et al. Dysregulated long non-coding RNAs in Parkinson’s disease contribute to the apoptosis of human neuroblastoma cells. Front Neurosci. 2019;13:1320. [DOI] [PubMed] [PMC]

100.

Bhattacharyya N, Pandey V, Bhattacharyya M, Dey A. Regulatory role of long non coding RNAs (lncRNAs) in neurological disorders: from novel biomarkers to promising therapeutic strategies. Asian J Pharm Sci. 2021;16:533–50. [DOI] [PubMed] [PMC]

101.

He S, Huang L, Shao C, Nie T, Xia L, Cui B, et al. Several miRNAs derived from serum extracellular vesicles are potential biomarkers for early diagnosis and progression of Parkinson’s disease. Transl Neurodegener. 2021;10:25. [DOI] [PubMed] [PMC]

102.

He H, Liu A, Zhang W, Yang H, Zhang M, Xu H, et al. Novel plasma miRNAs as biomarkers and therapeutic targets of Alzheimer’s disease at the prodromal stage. J Alzheimers Dis. 2021;83:779–90. [DOI] [PubMed]

103.

Chen FZ, Zhao Y, Chen HZ. MicroRNA-98 reduces amyloid β-protein production and improves oxidative stress and mitochondrial dysfunction through the Notch signaling pathway via HEY2 in Alzheimer’s disease mice. Int J Mol Med. 2019;43:91–102. [DOI] [PubMed] [PMC]

104.

Long JM, Ray B, Lahiri DK. MicroRNA-153 physiologically inhibits expression of amyloid-β precursor protein in cultured human fetal brain cells and is dysregulated in a subset of Alzheimer disease patients. J Biol Chem. 2012;287:31298–310. [DOI] [PubMed] [PMC]

105.

Geng L, Zhang T, Liu W, Chen Y. Inhibition of miR-128 Abates Aβ-mediated cytotoxicity by targeting PPAR-γ via NF-κB inactivation in primary mouse cortical neurons and Neuro2a cells. Yonsei Med J. 2018;59:1096–106. [DOI] [PubMed] [PMC]

106.

Li S, Poon CH, Zhang Z, Yue M, Chen R, Zhang Y, et al. MicroRNA-128 suppresses tau phosphorylation and reduces amyloid-beta accumulation by inhibiting the expression of GSK3β, APPBP2, and mTOR in Alzheimer’s disease. CNS Neurosci Ther. 2023;29:1848–64. [DOI] [PubMed] [PMC]

107.

Chen H, Shalom-Feuerstein R, Riley J, Zhang SD, Tucci P, Agostini M, et al. miR-7 and miR-214 are specifically expressed during neuroblastoma differentiation, cortical development and embryonic stem cells differentiation, and control neurite outgrowth in vitro. Biochem Biophys Res Commun. 2010;394:921–7. [DOI] [PubMed]

108.

Horsham JL, Ganda C, Kalinowski FC, Brown RAM, Epis MR, Leedman PJ. MicroRNA-7: a miRNA with expanding roles in development and disease. Int J Biochem Cell Biol. 2015;69:215–24. [DOI] [PubMed]

109.

Junn E, Lee KW, Jeong BS, Chan TW, Im JY, Mouradian MM. Repression of α-synuclein expression and toxicity by microRNA-7. Proc Natl Acad Sci U S A. 2009;106:13052–7. [DOI] [PubMed] [PMC]

110.

Padhi P, Worth C, Zenitsky G, Jin H, Sambamurti K, Anantharam V, et al. Mechanistic insights into gut microbiome dysbiosis-mediated neuroimmune dysregulation and protein misfolding and clearance in the pathogenesis of chronic neurodegenerative disorders. Front Neurosci. 2022;16:836605. [DOI] [PubMed] [PMC]

111.

Lv QK, Tao KX, Wang XB, Yao XY, Pang MZ, Liu JY, et al. Role of α-synuclein in microglia: autophagy and phagocytosis balance neuroinflammation in Parkinson’s disease. Inflamm Res. 2023;72:443–62. [DOI] [PubMed]

112.

Srinivasan E, Chandrasekhar G, Chandrasekar P, Anbarasu K, Vickram AS, Karunakaran R, et al. Alpha-synuclein aggregation in Parkinson’s disease. Front Med. 2021;8:736978. [DOI] [PubMed] [PMC]

113.

McMillan KJ, Murray TK, Bengoa-Vergniory N, Cordero-Llana O, Cooper J, Buckley A, et al. Loss of microRNA-7 regulation leads to α-synuclein accumulation and dopaminergic neuronal loss in vivo. Mol Ther. 2017;25:2404–14. [DOI] [PubMed] [PMC]

114.

Xu J, Zheng Y, Wang L, Liu Y, Wang X, Li Y, et al. miR-124: a promising therapeutic target for central nervous system injuries and diseases. Cell Mol Neurobiol. 2022;42:2031–53. [DOI] [PubMed]

115.

Thomas L, Florio T, Perez-Castro C. Extracellular vesicles loaded miRNAs as potential modulators shared between glioblastoma, and Parkinson’s and Alzheimer’s diseases. Front Cell Neurosci. 2020;14:590034. [DOI] [PubMed] [PMC]

116.

Yao L, Ye Y, Mao H, Lu F, He X, Lu G, et al. MicroRNA-124 regulates the expression of MEKK3 in the inflammatory pathogenesis of Parkinson’s disease. J Neuroinflammation. 2018;15:13. [DOI] [PubMed] [PMC]

117.

Li AD, Tong L, Xu N, Ye Y, Nie PY, Wang ZY, et al. miR-124 regulates cerebromicrovascular function in APP/PS1 transgenic mice via C1ql3. Brain Res Bull. 2019;153:214–22. [DOI] [PubMed]

118.

Esteves M, Abreu R, Fernandes H, Serra-Almeida C, Martins PAT, Barão M, et al. MicroRNA-124-3p-enriched small extracellular vesicles as a therapeutic approach for Parkinson’s disease. Mol Ther. 2022;30:3176–92. [DOI] [PubMed] [PMC]

119.

Rosenthal J, Tyor W. Aging, comorbidities, and the importance of finding biomarkers for HIV-associated neurocognitive disorders. J Neurovirol. 2019;25:673–85. [DOI] [PubMed] [PMC]

120.

Carroll A, Brew B. HIV-associated neurocognitive disorders: recent advances in pathogenesis, biomarkers, and treatment. F1000Res. 2017;6:312. [DOI] [PubMed] [PMC]

121.

Asahchop EL, Akinwumi SM, Branton WG, Fujiwara E, Gill MJ, Power C. Plasma microRNA profiling predicts HIV-associated neurocognitive disorder. AIDS. 2016;30:2021–31. [DOI] [PubMed]

122.

Pacifici M, Delbue S, Ferrante P, Jeansonne D, Kadri F, Nelson S, et al. Cerebrospinal fluid miRNA profile in HIV-encephalitis. J Cell Physiol. 2013;228:1070–5. [DOI] [PubMed] [PMC]

123.

Borrajo López A, Penedo MA, Rivera-Baltanas T, Pérez-Rodríguez D, Alonso-Crespo D, Fernández-Pereira C, et al. Microglia: the real foe in HIV-1-associated neurocognitive disorders? Biomedicines. 2021;9:925. [DOI] [PubMed] [PMC]

124.

Doke M, McLaughlin JP, Cai JJ, Pendyala G, Kashanchi F, Khan MA, et al. HIV-1 Tat and cocaine impact astrocytic energy reservoirs and epigenetic regulation by influencing the LINC01133-hsa-miR-4726-5p-NDUFA9 axis. Mol Ther Nucleic Acids. 2022;29:243–58. [DOI] [PubMed] [PMC]

125.

Periyasamy P, Thangaraj A, Bendi VS, Buch S. HIV-1 Tat-mediated microglial inflammation involves a novel miRNA-34a-NLRC5-NFκB signaling axis. Brain Behav Immun. 2019;80:227–37. [DOI] [PubMed] [PMC]

126.

Hu G, Liao K, Yang L, Pendyala G, Kook Y, Fox HS, et al. Tat-mediated induction of miRs-34a & -138 promotes astrocytic activation via downregulation of SIRT1: implications for aging in HAND. J Neuroimmune Pharmacol. 2017;12:420–32. [DOI] [PubMed] [PMC]

127.

Xu Z, Asahchop EL, Branton WG, Gelman BB, Power C, Hobman TC. MicroRNAs upregulated during HIV infection target peroxisome biogenesis factors: implications for virus biology, disease mechanisms and neuropathology. PLoS Pathog. 2017;13:e1006360. [DOI] [PubMed] [PMC]

128.

Stoicea N, Du A, Lakis DC, Tipton C, Arias-Morales CE, Bergese SD. The miRNA journey from theory to practice as a CNS biomarker. Front Genet. 2016;7:11. [DOI] [PubMed] [PMC]

129.

Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Gene. 2009;10:155–9. [DOI] [PubMed]

130.

Srinivas T, Mathias C, Oliveira-Mateos C, Guil S. Roles of lncRNAs in brain development and pathogenesis: emerging therapeutic opportunities. Mol Ther. 2023;31:1550–61. [DOI] [PubMed]

131.

Amaral PP, Mattick JS. Noncoding RNA in development. Mamm Genome. 2008;19:454–92. [DOI] [PubMed]

132.

Faghihi MA, Modarresi F, Khalil AM, Wood DE, Sahagan BG, Morgan TE, et al. Expression of a noncoding RNA is elevated in Alzheimer’s disease and drives rapid feed-forward regulation of beta-secretase. Nat Med. 2008;14:723–30. [DOI] [PubMed] [PMC]

133.

Gu C, Chen C, Wu R, Dong T, Hu X, Yao Y, et al. Long noncoding RNA EBF3-AS promotes neuron apoptosis in Alzheimer’s disease. DNA Cell Biol. 2018;37:220–6. [DOI] [PubMed]

134.

Gao Y, Zhang N, Lv C, Li N, Li X, Li W. lncRNA SNHG1 knockdown alleviates amyloid-β-induced neuronal injury by regulating ZNF217 via sponging miR-361-3p in Alzheimer’s disease. J Alzheimers Dis. 2020;77:85–98. [DOI] [PubMed]

135.

Ciarlo E, Massone S, Penna I, Nizzari M, Gigoni A, Dieci G, et al. An intronic ncRNA-dependent regulation of SORL1 expression affecting Aβ formation is upregulated in post-mortem Alzheimer’s disease brain samples. Dis Model Mech. 2013;6:424–33. [DOI] [PubMed] [PMC]

136.

Honarmand Tamizkar K, Gorji P, Gholipour M, Hussen BM, Mazdeh M, Eslami S, et al. Parkinson’s disease is associated with dysregulation of circulatory levels of lncRNAs. Front Immunol. 2021;12:763323. [DOI] [PubMed] [PMC]

137.

Hossein-Nezhad A, Fatemi RP, Ahmad R, Peskind ER, Zabetian CP, Hu SC, et al. Transcriptomic profiling of extracellular RNAs present in cerebrospinal fluid identifies differentially expressed transcripts in Parkinson’s disease. J Parkinsons Dis. 2016;6:109–17. [DOI] [PubMed] [PMC]

138.

Coupland KG, Kim WS, Halliday GM, Hallupp M, Dobson-Stone C, Kwok JB. Role of the long non-coding RNA MAPT-AS1 in regulation of microtubule associated protein tau (MAPT) expression in Parkinson’s disease. PLoS One. 2016;11:e0157924. [DOI] [PubMed] [PMC]

139.

Guan X, Sun Y, Zhang C. LncRNAs in blood cells: roles in cell development and potential pathogenesis in hematological malignancies. Crit Rev Oncol Hematol. 2022;180:103849. [DOI] [PubMed]

140.

Ni Y, Huang H, Chen Y, Cao M, Zhou H, Zhang Y. Investigation of long non-coding RNA expression profiles in the substantia nigra of Parkinson’s disease. Cell Mol Neurobiol. 2017;37:329–38. [DOI] [PubMed]

141.

Xu W, Zhang L, Geng Y, Liu Y, Zhang N. Long noncoding RNA GAS5 promotes microglial inflammatory response in Parkinson’s disease by regulating NLRP3 pathway through sponging miR-223-3p. Int Immunopharmacol. 2020;85:106614. [DOI] [PubMed]

142.

Peng T, Liu X, Wang J, Liu Y, Fu Z, Ma X, et al. Long noncoding RNA HAGLROS regulates apoptosis and autophagy in Parkinson’s disease via regulating miR-100/ATG10 axis and PI3K/Akt/mTOR pathway activation. Artif Cells Nanomed Biotechnol. 2019;47:2764–74. [DOI] [PubMed]

143.

Simchovitz A, Hanan M, Yayon N, Lee S, Bennett ER, Greenberg DS, et al. A lncRNA survey finds increases in neuroprotective LINC-PINT in Parkinson’s disease substantia nigra. Aging Cell. 2020;19:e13115. [DOI] [PubMed] [PMC]

144.

Xu X, Zhuang C, Wu Z, Qiu H, Feng H, Wu J. LincRNA-p21 inhibits cell viability and promotes cell apoptosis in Parkinson’s disease through activating α-synuclein expression. Biomed Res Int. 2018;2018:8181374. [DOI] [PubMed] [PMC]

145.

Liu L, Zhou T, Li T, Liang Z, Luo X. LncRNA DLX6-AS1 promotes microglial inflammatory response in Parkinson’s disease by regulating the miR-223–3p/NRP1 axis. Behav Brain Res. 2022;431:113923. [DOI] [PubMed]

146.

Ramos AD, Diaz A, Nellore A, Delgado RN, Park KY, Gonzales-Roybal G, et al. Integration of genome-wide approaches identifies lncRNAs of adult neural stem cells and their progeny in vivo. Cell Stem Cell. 2013;12:616–28. [DOI] [PubMed] [PMC]

147.

Jin XF, Wu N, Wang L, Li J. Circulating microRNAs: a novel class of potential biomarkers for diagnosing and prognosing central nervous system diseases. Cell Mol Neurobiol. 2013;33:601–13. [DOI] [PubMed]

148.

Krsmanovic P, Mocikova H, Chramostova K, Klanova M, Trnkova M, Pesta M, et al. Circulating microRNAs in cerebrospinal fluid and plasma: sensitive tool for detection of secondary CNS involvement, monitoring of therapy and prediction of CNS relapse in aggressive B-NHL lymphomas. Cancers (Basel). 2022;14:2305. [DOI] [PubMed] [PMC]

149.

Lippi G, Steinert JR, Marczylo EL, D’Oro S, Fiore R, Forsythe ID, et al. Targeting of the Arpc3 actin nucleation factor by miR-29a/b regulates dendritic spine morphology. J Cell Biol. 2011;194:889–904. [DOI] [PubMed] [PMC]

150.

Kole AJ, Swahari V, Hammond SM, Deshmukh M. miR-29b is activated during neuronal maturation and targets BH3-only genes to restrict apoptosis. Genes Dev. 2011;25:125–30. [DOI] [PubMed] [PMC]

151.

Mei Z, Liu J, Schroeder JP, Weinshenker D, Duong DM, Seyfried NT, et al. Lowering hippocampal miR-29a expression slows cognitive decline and reduces beta-amyloid deposition in 5×FAD mice. Mol Neurobiol. 2023. [DOI] [PubMed]

152.

Johnson R, Zuccato C, Belyaev ND, Guest DJ, Cattaneo E, Buckley NJ. A microRNA-based gene dysregulation pathway in Huntington’s disease. Neurobiol Dis. 2008;29:438–45. [DOI] [PubMed]

153.

Smith KM, Guerau-de-Arellano M, Costinean S, Williams JL, Bottoni A, Mavrikis Cox G, et al. miR-29ab1 deficiency identifies a negative feedback loop controlling Th1 bias that is dysregulated in multiple sclerosis. J Immunol. 2012;189:1567–76. [DOI] [PubMed] [PMC]

154.

Bai X, Tang Y, Yu M, Wu L, Liu F, Ni J, et al. Downregulation of blood serum microRNA 29 family in patients with Parkinson’s disease. Sci Rep. 2017;7:5411. [DOI] [PubMed] [PMC]

155.

Zhao M, Gao J, Zhang Y, Jiang X, Tian Y, Zheng X, et al. Elevated miR-29a contributes to axonal outgrowth and neurological recovery after intracerebral hemorrhage via targeting PTEN/PI3K/Akt pathway. Cell Mol Neurobiol. 2021;41:1759–72. [DOI] [PubMed]

156.

Xie B, Zhou H, Zhang R, Song M, Yu L, Wang L, et al. Serum miR-206 and miR-132 as potential circulating biomarkers for mild cognitive impairment. J Alzheimers Dis. 2015;45:721–31. [DOI] [PubMed]

157.

Salama RM, Abdel-Latif GA, Abbas SS, El Magdoub HM, Schaalan MF. Neuroprotective effect of crocin against rotenone-induced Parkinson’s disease in rats: interplay between PI3K/Akt/mTOR signaling pathway and enhanced expression of miRNA-7 and miRNA-221. Neuropharmacology. 2020;164:107900. [DOI] [PubMed]

158.

Wang H, Peng R, Wang J, Qin Z, Xue L. Circulating microRNAs as potential cancer biomarkers: the advantage and disadvantage. Clin Epigenetics. 2018;10:59. [DOI] [PubMed] [PMC]

159.

Marrone AK, Beland FA, Pogribny IP. Noncoding RNA response to xenobiotic exposure: an indicator of toxicity and carcinogenicity. Expert Opin Drug Metab Toxicol. 2014;10:1409–22. [DOI] [PubMed]

160.

Xiang Y, Xin J, Le W, Yang Y. Neurogranin: a potential biomarker of neurological and mental diseases. Front Aging Neurosci. 2020;12:584743. [DOI] [PubMed] [PMC]

161.

Zou K, Abdullah M, Michikawa M. Current biomarkers for Alzheimer’s disease: from CSF to blood. J Pers Med. 2020;10:85. [DOI] [PubMed] [PMC]

162.

Hoffman L, Chandrasekar A, Wang X, Putkey JA, Waxham MN. Neurogranin alters the structure and calcium binding properties of calmodulin. J Biol Chem. 2014;289:14644–55. [DOI] [PubMed] [PMC]

163.

Dulewicz M, Kulczyńska-Przybik A, Słowik A, Borawska R, Mroczko B. Neurogranin and neuronal pentraxin receptor as synaptic dysfunction biomarkers in Alzheimer’s disease. J Clin Med. 2021;10:4575. [DOI] [PubMed] [PMC]

164.

Betancor M, Pérez-Lázaro S, Otero A, Marín B, Martín-Burriel I, Blennow K, et al. Neurogranin and neurofilament light Chain as preclinical biomarkers in scrapie. Int J Mol Sci. 2022;23:7182. [DOI] [PubMed] [PMC]

165.

Esteve C, Jones EA, Kell DB, Boutin H, McDonnell LA. Mass spectrometry imaging shows major derangements in neurogranin and in purine metabolism in the triple-knockout 3×Tg Alzheimer mouse model. Biochim Biophys Acta Proteins Proteom. 2017;1865:747–54. [DOI] [PubMed]

166.

George AJ, Gordon L, Beissbarth T, Koukoulas I, Holsinger RMD, Perreau V, et al. A serial analysis of gene expression profile of the Alzheimer’s disease Tg2576 mouse model. Neurotox Res. 2010;17:360–79. [DOI] [PubMed]

167.

Liu W, Lin H, He X, Chen L, Dai Y, Jia W, et al. Neurogranin as a cognitive biomarker in cerebrospinal fluid and blood exosomes for Alzheimer’s disease and mild cognitive impairment. Transl Psychiatry. 2020;10:125. [DOI] [PubMed] [PMC]

168.

Pak JH, Huang FL, Li J, Balschun D, Reymann KG, Chiang C, et al. Involvement of neurogranin in the modulation of calcium/calmodulin-dependent protein kinase II, synaptic plasticity, and spatial learning: a study with knockout mice. Proc Natl Acad Sci U S A. 2000;97:11232–7. [DOI] [PubMed] [PMC]

169.

Kaleka KS, Gerges NZ. Neurogranin restores amyloid β-mediated synaptic transmission and long-term potentiation deficits. Exp Neurol. 2016;277:115–23. [DOI] [PubMed]

170.

Guha D, Wagner MCE, Ayyavoo V. Human immunodeficiency virus type 1 (HIV-1)-mediated neuroinflammation dysregulates neurogranin and induces synaptodendritic injury. J Neuroinflammation. 2018;15:126. [DOI] [PubMed] [PMC]

171.

Ellis R, Langford D, Masliah E. HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat Rev Neurosci. 2007;8:33–44. [DOI] [PubMed]

172.

Yilmaz A, Fuchs D, Price RW, Spudich S, Blennow K, Zetterberg H, et al. Cerebrospinal fluid concentrations of the synaptic marker neurogranin in neuro-HIV and other neurological disorders. Curr HIV/AIDS Rep. 2019;16:76–81. [DOI] [PubMed] [PMC]

173.

Saunders T, Gunn C, Blennow K, Kvartsberg H, Zetterberg H, Shenkin SD, et al. Neurogranin in Alzheimer’s disease and ageing: a human post-mortem study. Neurobiol Dis. 2023;177:105991. [DOI] [PubMed]

174.

Hall S, Janelidze S, Zetterberg H, Brix B, Mattsson N, Surova Y, et al. Cerebrospinal fluid levels of neurogranin in Parkinsonian disorders. Mov Disord. 2020;35:513–8. [DOI] [PubMed]

175.

Willemse EAJ, Sieben A, Somers C, Vermeiren Y, De Roeck N, Timmers M, et al. Neurogranin as biomarker in CSF is non-specific to Alzheimer’s disease dementia. Neurobiol Aging. 2021;108:99–109. [DOI] [PubMed]

176.

Nilsson J, Constantinescu J, Nellgård B, Jakobsson P, Brum WS, Gobom J, et al. Cerebrospinal fluid biomarkers of synaptic dysfunction are altered in Parkinson’s disease and related disorders. Mov Disord. 2022;38:267–77. [DOI] [PubMed]

177.

Yuan A, Rao MV, Veeranna, Nixon RA. Neurofilaments and neurofilament proteins in health and disease. Cold Spring Harb Perspect Biol. 2017;9:a018309. [DOI] [PubMed] [PMC]

178.

Yuan A, Nixon RA. Neurofilament proteins as biomarkers to monitor neurological diseases and the efficacy of therapies. Front Neurosci. 2021;15:689938. [DOI] [PubMed] [PMC]

179.

Bittner S, Oh J, Havrdová EK, Tintoré M, Zipp F. The potential of serum neurofilament as biomarker for multiple sclerosis. Brain. 2021;144:2954–63. [DOI] [PubMed] [PMC]

180.

Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14:577–89. [DOI] [PubMed]

181.

Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry. 2019;90:870–81. [DOI] [PubMed]

182.

Niemelä V, Landtblom AM, Blennow K, Sundblom J. Tau or neurofilament light—Which is the more suitable biomarker for Huntington’s disease? PLoS One. 2017;12:e0172762. [DOI] [PubMed] [PMC]

183.

Gisslén M, Price RW, Andreasson U, Norgren N, Nilsson S, Hagberg L, et al. Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study. EBioMedicine. 2016;3:135–40. [DOI] [PubMed] [PMC]

184.

Anderson AM, Easley KA, Kasher N, Franklin D, Heaton RK, Zetterberg H, et al. Neurofilament light chain in blood is negatively associated with neuropsychological performance in HIV-infected adults and declines with initiation of antiretroviral therapy. J Neurovirol. 2018;24:695–701. [DOI] [PubMed] [PMC]

185.

Ullah R, Park TJ, Huang X, Kim MO. Abnormal amyloid beta metabolism in systemic abnormalities and Alzheimer’s pathology: insights and therapeutic approaches from periphery. Ageing Res Rev. 2021;71:101451. [DOI] [PubMed]

186.

Kwak SS, Washicosky KJ, Brand E, von Maydell D, Aronson J, Kim S, et al. Amyloid-β42/40 ratio drives tau pathology in 3D human neural cell culture models of Alzheimer’s disease. Nat Commun. 2020;11:1377. [DOI] [PubMed] [PMC]

187.

Jana AK, Güven Ö, Yaşar F. The stability and dynamics of the Aβ40/Aβ42 interlaced mixed fibrils. J Biomol Struct Dyn. 2023:1–14. [DOI] [PubMed]

188.

Baldeiras I, Santana I, Leitão MJ, Gens H, Pascoal R, Tábuas-Pereira M, et al. Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer’s disease dementia in mild cognitive impairment. Alzheimers Res Ther. 2018;10:33. [DOI] [PubMed] [PMC]

189.

Palmqvist S, Janelidze S, Stomrud E, Zetterberg H, Karl J, Zink K, et al. Performance of fully automated plasma assays as screening tests for Alzheimer disease-related β-amyloid status. JAMA Neurol. 2019;76:1060–9. [DOI] [PubMed] [PMC]

190.

West T, Kirmess KM, Meyer MR, Holubasch MS, Knapik SS, Hu Y, et al. A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis. Mol Neurodegener. 2021;16:30. [DOI] [PubMed] [PMC]

191.

Shi D, Zhang L, Guo T; Alzheimer’s Disease Neuroimaging Initiative. High precision plasma Aβ₄₂/Aβ₄₀ ratio detects early amyloid deposition in non‐demented elderly adults. Alzheimers Dement. 2021;17:e053343. [DOI]

192.

Honda K, Saito Y, Saito H, Toyoda M, Abe R, Saito T, et al. Accumulation of amyloid-β in the brain of mouse models of Alzheimer’s disease is modified by altered gene expression in the presence of human apoE isoforms during aging. Neurobiol Aging. 2023;123:63–74. [DOI] [PubMed]

193.

Andersson E, Saito T, Saido TC, Blennow K, Zetterberg H, Hansson O. Reduced CSF Aβ42 and Aβ42/Aβ40 ratio during early cerebral amyloid deposition in the App^NL-F knock-in mouse model of Alzheimer’s disease. Alzheimers Dement. 2022;18. [DOI]

194.

Amft M, Ortner M, Eichenlaub U, Goldhardt O, Diehl-Schmid J, Hedderich DM, et al. The cerebrospinal fluid biomarker ratio Aβ42/40 identifies amyloid positron emission tomography positivity better than Aβ42 alone in a heterogeneous memory clinic cohort. Alzheimers Res Ther. 2022;14:60. [DOI] [PubMed] [PMC]

195.

Vanderstichele HMJ, Janelidze S, Demeyer L, Coart E, Stoops E, Herbst V, et al. Optimized standard operating procedures for the analysis of cerebrospinal fluid Aβ₄₂ and the ratios of Aβ isoforms using low protein binding tubes. J Alzheimers Dis. 2016;53:1121–32. [DOI] [PubMed] [PMC]

196.

Pascual-Lucas M, Allué JA, Sarasa L, Fandos N, Castillo S, Terencio J, et al. Clinical performance of an antibody-free assay for plasma Aβ42/Aβ40 to detect early alterations of Alzheimer’s disease in individuals with subjective cognitive decline. Alzheimers Res Ther. 2023;15:2. [DOI] [PubMed] [PMC]

197.

Janelidze S, Palmqvist S, Leuzy A, Stomrud E, Verberk IMW, Zetterberg H, et al. Detecting amyloid positivity in early Alzheimer’s disease using combinations of plasma Aβ42/Aβ40 and p-tau. Alzheimers Dement. 2022;18:283–93. [DOI] [PubMed]

198.

Fandos N, Pérez-Grijalba V, Pesini P, Olmos S, Bossa M, Villemagne VL, et al.; AIBL Research Group. Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals. Alzheimers Dement (Amst). 2017;8:179–87. [DOI] [PubMed] [PMC]

199.

Cullen NC, Janelidze S, Mattsson-Carlgren N, Palmqvist S, Bittner T, Suridjan I, et al. Test-retest variability of plasma biomarkers in Alzheimer’s disease and its effects on clinical prediction models. Alzheimers Dement. 2023;19:797–806. [DOI] [PubMed] [PMC]

200.

Hu Y, Kirmess KM, Meyer MR, Rabinovici GD, Gatsonis C, Siegel BA, et al. Assessment of a plasma amyloid probability score to estimate amyloid positron emission tomography findings among adults with cognitive impairment. JAMA Netw Open. 2022;5:e228392. [DOI] [PubMed] [PMC]

201.

Vergallo A, Mégret L, Lista S, Cavedo E, Zetterberg H, Blennow K, et al. Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer’s disease. Alzheimers Dement. 2019;15:764–75. [DOI] [PubMed]

202.

Bun S, Ito D, Tezuka T, Kubota M, Ueda R, Takahata K, et al. Performance of plasma Aβ42/40, measured using a fully automated immunoassay, across a broad patient population in identifying amyloid status. Alzheimers Res Ther. 2023;15:149. [DOI] [PubMed] [PMC]

203.

Sturchio A, Dwivedi AK, Malm T, Wood MJA, Cilia R, Sharma JS, et al. High soluble amyloid-β₄₂ predicts normal cognition in amyloid-positive individuals with Alzheimer’s disease-causing mutations. J Alzheimers Dis. 2022;90:333–48. [DOI] [PubMed] [PMC]

204.

Zhu X, Schrader JM, Irizarry BA, Smith SO, Van Nostrand WE. Impact of Aβ40 and Aβ42 fibrils on the transcriptome of primary astrocytes and microglia. Biomedicines. 2022;10:2982. [DOI] [PubMed] [PMC]

205.

Janelidze S, Teunissen CE, Zetterberg H, Allué JA, Sarasa L, Eichenlaub U, et al. Head-to-head comparison of 8 plasma amyloid-β 42/40 assays in Alzheimer disease. JAMA Neurol. 2021;78:1375–82. [DOI] [PubMed] [PMC]

206.

Fan Z, Li Z, Zhao S, Chen Y, Su Y, Peng G, et al. Salivary Aβ_1–42 may be a quick-tested biomarker for clinical use in Alzheimer’s disease: a meta-analysis. J Neurol. 2023;270:1945–54. [DOI] [PubMed]

207.

Sinsky J, Pichlerova K, Hanes J. Tau protein interaction partners and their roles in Alzheimer’s disease and other tauopathies. Int J Mol Sci. 2021;22:9207. [DOI] [PubMed] [PMC]

208.

Barbier P, Zejneli O, Martinho M, Lasorsa A, Belle V, Smet-Nocca C, et al. Role of tau as a microtubule-associated protein: structural and functional aspects. Front Aging Neurosci. 2019;10:204. [DOI] [PubMed] [PMC]

209.

Kanaan NM, Grabinski T. Neuronal and glial distribution of tau protein in the adult rat and monkey. Front Mol Neurosci. 2021;14:607303. [DOI] [PubMed] [PMC]

210.

Haque MM, Murale DP, Kim YK, Lee JS. Crosstalk between oxidative stress and tauopathy. Int J Mol Sci. 2019;20:1959. [DOI] [PubMed] [PMC]

211.

Ashton NJ, Benedet AL, Pascoal TA, Karikari TK, Lantero-Rodriguez J, Brum WS, et al. Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer’s disease. EBioMedicine. 2022;76:103836. [DOI] [PubMed] [PMC]

212.

Gonzalez-Ortiz F, Kac PR, Brum WS, Zetterberg H, Blennow K, Karikari TK. Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications. Mol Neurodegener. 2023;18:18. [DOI] [PubMed] [PMC]

213.

Milà-Alomà M, Ashton NJ, Shekari M, Salvadó G, Ortiz-Romero P, Montoliu-Gaya L, et al. Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease. Nat Med. 2022;28:1797–801. [DOI] [PMC]

214.

Mattsson-Carlgren N, Janelidze S, Palmqvist S, Cullen N, Svenningsson AL, Strandberg O, et al. Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease. Brain. 2021;143:3234–41. [DOI] [PubMed] [PMC]

215.

Lussier FZ, Benedet AL, Therriault J, Pascoal TA, Tissot C, Chamoun M, et al. Plasma levels of phosphorylated tau 181 are associated with cerebral metabolic dysfunction in cognitively impaired and amyloid-positive individuals. Brain Commun. 2021;3:fcab073. [DOI] [PubMed] [PMC]

216.

Tissot C, Benedet AL, Therriault J, Pascoal TA, Lussier FZ, Saha-Chaudhuri P, et al. Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer’s disease. Alzheimers Res Ther. 2021;13:69. [DOI] [PubMed] [PMC]

217.

O’Connor A, Karikari TK, Poole T, Ashton NJ, Lantero Rodriguez J, Khatun A, et al. Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer’s disease: a longitudinal cohort study. Mol Psychiatry. 2021;26:5967–76. [DOI] [PubMed] [PMC]

218.

Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;324:772–81. [DOI] [PubMed] [PMC]

219.

Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer’s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19:422–33. [DOI] [PubMed]

220.

Hansson O, Cullen N, Zetterberg H, Blennow K, Mattsson-Carlgren N; Alzheimer’s Disease Neuroimaging Initiative. Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease. Ann Clin Transl Neurol. 2021;8:259–65. [DOI] [PubMed] [PMC]

221.

Suárez-Calvet M, Karikari TK, Ashton NJ, Lantero Rodríguez J, Milà-Alomà M, Gispert JD, et al. Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected. EMBO Mol Med. 2020;12:e12921. [DOI] [PubMed] [PMC]

222.

Schindler SE, Karikari TK, Ashton NJ, Henson RL, Yarasheski KE, West T, et al. Effect of race on prediction of brain amyloidosis by plasma Aβ42/Aβ40, phosphorylated tau, and neurofilament light. Neurology. 2022;99:e245–57. [DOI] [PubMed] [PMC]

223.

Dendrou CA, McVean G, Fugger L. Neuroinflammation — using big data to inform clinical practice. Nat Rev Neurol. 2016;12:685–98. [DOI] [PubMed]

224.

Doroszkiewicz J, Groblewska M, Mroczko B. Molecular biomarkers and their implications for the early diagnosis of selected neurodegenerative diseases. Int J Mol Sci. 2022;23:4610. [DOI] [PubMed] [PMC]

225.

Cabús L, Lagarde J, Curado J, Lizano E, Pérez-Boza J. Current challenges and best practices for cell-free long RNA biomarker discovery. Biomark Res. 2022;10:62. [DOI] [PubMed] [PMC]

226.

Bose N, Brookes AJ, Scordis P, Visser PJ. Data and sample sharing as an enabler for large-scale biomarker research and development: the EPND perspective. Front Neurol. 2022;13:1031091. [DOI] [PubMed] [PMC]

227.

Young PNE, Estarellas M, Coomans E, Srikrishna M, Beaumont H, Maass A, et al. Imaging biomarkers in neurodegeneration: current and future practices. Alzheimers Res Ther. 2020;12:49. [DOI] [PubMed] [PMC]

228.

Karami E, Soliman H, Ruschin M, Sahgal A, Myrehaug S, Tseng CL, et al. Quantitative MRI biomarkers of stereotactic radiotherapy outcome in brain metastasis. Sci Rep. 2019;9:19830. [DOI] [PubMed] [PMC]

229.

Ughi GJ, Gora MJ, Swager AF, Soomro A, Grant C, Tiernan A, et al. Automated segmentation and characterization of esophageal wall in vivo by tethered capsule optical coherence tomography endomicroscopy. Biomed Opt Express. 2016;7:409–19. [DOI] [PubMed] [PMC]

230.

Waterhouse DJ, Fitzpatrick CRM, Pogue BW, O’Connor JPB, Bohndiek SE. A roadmap for the clinical implementation of optical-imaging biomarkers. Nat Biomed Eng. 2019;3:339–53. [DOI] [PubMed]

231.

Davies HE, Wathen CG, Gleeson FV. The risks of radiation exposure related to diagnostic imaging and how to minimise them. BMJ. 2011;342:d947. [DOI] [PubMed]

232.

Chew S, Atassi N. Positron emission tomography molecular imaging biomarkers for amyotrophic lateral sclerosis. Front Neurol. 2019;10:135. [DOI] [PubMed] [PMC]

233.

Pilotto Heming C, Niemeyer Filho P, Moura-Neto V, Aran V. Recent advances in the use of liquid biopsy to fight central nervous system tumors. Cancer Treat Res Commun. 2023;35:100709. [DOI] [PubMed]

234.

Warren JD, Schott JM, Fox NC, Thom M, Revesz T, Holton JL, et al. Brain biopsy in dementia. Brain. 2005;128:2016–25. [DOI] [PubMed]

235.

Meyer K, Kaspar BK. Glia–neuron interactions in neurological diseases: testing non-cell autonomy in a dish. Brain Res. 2017;1656:27–39. [DOI] [PubMed] [PMC]

236.

Bellassai N, D’Agata R, Jungbluth V, Spoto G. Surface plasmon resonance for biomarker detection: advances in non-invasive cancer diagnosis. Front Chem. 2019;7:570. [DOI] [PubMed] [PMC]

237.

Qin F, Huang Z, Dong Q, Xu X, Lu T, Chen J, et al. Stereotactic biopsy for lesions in brainstem and deep brain: a single-center experience of 72 cases. Braz J Med Biol Res. 2021;54:e11335. [DOI] [PubMed] [PMC]

238.

Hirano Y, Shinya Y, Aono T, Hasegawa H, Kawashima M, Shin M, et al. The role of stereotactic frame-based biopsy for brainstem tumors in the era of molecular-based diagnosis and treatment decisions. Curr Oncol. 2022;29:4558–65. [DOI] [PubMed] [PMC]

239.

Grizzl WE. Issues in the use of human tissues to support precision medicine. J Health Care Poor Underserved. 2019;30:66–78. [DOI] [PubMed] [PMC]

240.

Dakappagari N, Zhang H, Stephen L, Amaravadi L, Khan MU. Recommendations for clinical biomarker specimen preservation and stability assessments. Bioanalysis. 2017;9:643–53. [DOI] [PubMed]

241.

Jain N. Essentials before sending biopsy specimens: a surgeon’s prespective and pathologists concern. J Maxillofac Oral Surg. 2011;10:361–4. [DOI] [PubMed] [PMC]

242.

Arias JJ, Phillips KA, Karlawish J. Developing an economic and policy research agenda for blood biomarkers of neurodegenerative diseases. JAMA Health Forum. 2021;2:e211428. [DOI] [PubMed]

243.

Villa C, Lavitrano M, Salvatore E, Combi R. Molecular and imaging biomarkers in Alzheimer’s disease: a focus on recent insights. J Pers Med. 2020;10:62. [DOI] [PubMed] [PMC]